Related stories
InnoCare Says Orelabrutinib Phase III ITP Study Met Primary Endpoint
InnoCare announced Phase III results for orelabrutinib in an ITP study, saying the trial met its primary endpoint.
L impact | EQUITY | Nov 05, 2026, 10:37 AM UTC
RENK CEO Says Modular Production Rollout Will Raise Near-Term Costs
RENK’s CEO said the modular production concept rollout will drive higher production costs in the near term.
M impact | EQUITY | Nov 05, 2026, 10:37 AM UTC
Rubicon Research reports Q2 consolidated revenue of INR 5,763.8 million
M impact | EQUITY | Nov 05, 2026, 10:35 AM UTC
Anders Invest Acquires 60% Stake in Matco International
M impact | EQUITY | Nov 05, 2026, 10:35 AM UTC
Rubicon Research Reports Q2 Consolidated Net Profit of INR 904.8 Million
M impact | EQUITY | Nov 05, 2026, 10:34 AM UTC
Sailun Produces First Tire at $804 Million SCZONE Plant
China's Sailun produced its first tire at the $804 million plant in Egypt's Suez Canal Economic Zone.
M impact | EQUITY | Nov 05, 2026, 10:34 AM UTC